Great Point Invests in Cytovance

Great Point Partners has provided Cytovance Biologics with $22.5 million of growth equity. Cytovance is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from mammalian cell culture and microbial fermentation. The company plans to use the new capital to fund facility, service and personnel expansion at its advanced research and manufacturing operation in Oklahoma City.